Tirzepatide may reduce blood pressure in patients with a BMI of 27 or higher, both during the day and at night. The SURMOUNT-1 trial evaluated the effects of tirzepatide on blood pressure in adults with high BMI. The study showed that all doses of tirzepatide led to a decrease in 24-hour systolic blood pressure compared to placebo. The medication also resulted in lower diastolic blood pressure, with an increase in heart rate. The study suggests that tirzepatide may have potential benefits for cardiometabolic health and cardiovascular outcomes. However, the study had limitations, and further research is needed. The trial was supported by Eli Lilly and Company.
Source link
Tirzepatide May Lower Blood Pressure in Patients With Obesity
